CD8A and neoplasm: Similarly, we also demonstrate that either the pharmacological inhibitor A196 or the genetic inhibition of KMT5C can not only restore CD8+ T cell function and suppress tumor growth, but can also promote the efficacy of anti‐PD‐1 therapy in NSCLC.